Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 7:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–88 of 88 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Fragile X Syndrome Clear all

Conditions: Autism Spectrum Disorders, Psychosis, Fragile X Syndrome
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 3 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Fragile X Syndrome
Interventions: Not listed
Lead sponsor: Esoterix Genetic Laboratories, LLC; Industry
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Westborough, Massachusetts

Conditions: Fragile X Syndrome
Interventions: STX107; Drug
Lead sponsor: Seaside Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 5
States / cities: Los Angeles, California • Sacramento, California • Aurora, Colorado + 2 more

Conditions: Fragile X Associated Tremor-ataxia Syndrome
Interventions: Dual-Task Treadmill exercise + Cognitive Training; Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 50 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Fragile X Syndrome, Intellectual Disability
Interventions: Social gaze training; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 8 Years to 18 Years · Male only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Stanford, California

Conditions: Fragile X Syndrome
Interventions: Riluzole; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Fragile X Syndrome
Interventions: AFQ056; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 3 Years to 11 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Sacramento, California • Chicago, Illinois • Nashville, Tennessee

Conditions: Fragile X Syndrome
Interventions: Speech discrimination; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 24 Months to 4 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Fragile X Syndrome
Interventions: acamprosate, Placebo; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 5 Years to 23 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Chicago, Illinois • Cincinnati, Ohio

Conditions: Fragile X Syndrome, Fragile X Mental Retardation Syndrome, Mental Retardation, X Linked, Genetic Diseases, X-Linked, Trinucleotide Repeat Expansion, Fra(X) Syndrome, Intellectual Disability, FXS, Neurobehavioral Manifestations, Sex Chromosome Disorders
Interventions: Placebo Medication, Metformin; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 6 Years to 25 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Fragile X Syndrome
Interventions: Working Memory Training; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 8 Years to 18 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Fragile X Syndrome
Interventions: AFQ056; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 10
States / cities: Phoenix, Arizona • Sacramento, California • Decatur, Georgia + 7 more

Conditions: Fragile X Syndrome
Interventions: ZYN002 - Cannabidiol Transdermal Gel; Drug
Lead sponsor: Zynerba Pharmaceuticals, Inc.; Industry
Eligibility: 3 Years to 29 Years
Enrollment: 476 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 19
States / cities: Phoenix, Arizona • Culver City, California • Irvine, California + 16 more

Conditions: Fragile X Syndrome, FXS, Fra(X) Syndrome
Interventions: BPN14770, Placebo; Drug
Lead sponsor: Tetra Discovery Partners; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Fragile X Syndrome
Interventions: AFQ056, Placebo, Language Intervention; Drug · Other
Lead sponsor: Elizabeth Berry-Kravis; Other
Eligibility: 32 Months to 6 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 14
States / cities: Davis, California • Denver, Colorado • New Haven, Connecticut + 11 more

Conditions: Angelman Syndrome, Fragile X Syndrome
Interventions: OV101; Drug
Lead sponsor: Ovid Therapeutics Inc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 2
States / cities: Chicago, Illinois • Nashville, Tennessee

Search by objective public record fields.

Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment

Validation of Saliva in the Esoterix Genetic Laboratories Fragile X Assay

A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome

Treadmill Training in Fragile X-associated Tremor/Ataxia Syndrome

Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome

Riluzole in Fragile X Syndrome

Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)

Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG-Preschool Age

Study of Acamprosate in Fragile x Syndrome

A Trial of Metformin in Individuals With Fragile X Syndrome

Cognitive Training for Fragile X Syndrome

Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X Syndrome

Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS

A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome

AFQ056 for Language Learning in Children With FXS

Single Dose Pharmacokinetic (PK) Study